PharmGKB summary: cyclosporine and tacrolimus pathways

被引:191
作者
Barbarino, Julia M. [1 ]
Staatz, Christine E. [5 ]
Venkataramanan, Raman [3 ,4 ]
Klein, Teri E. [1 ]
Altman, Russ B. [2 ]
机构
[1] Stanford Univ, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
[3] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Sch Med, Dept Pathol, Starzl Transplantat Inst, Pittsburgh, PA USA
[5] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
基金
美国国家卫生研究院;
关键词
ABCB1; calcineurin; cyclosporine; CYP3A4; CYP3A5; pharmacodynamics; pharmacogenetics; pharmacokinetics; tacrolimus; transplantation; SINGLE-NUCLEOTIDE POLYMORPHISMS; RENAL-TRANSPLANT RECIPIENTS; MULTIDRUG-RESISTANCE GENE; GROWTH-FACTOR-BETA; EFFLUX TRANSPORT ACTIVITY; BLOOD MONONUCLEAR-CELLS; ACUTE REJECTION RATES; NF-KAPPA-B; P-GLYCOPROTEIN; DOSE REQUIREMENTS;
D O I
10.1097/FPC.0b013e328364db84
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
[No abstract available]
引用
收藏
页码:563 / 585
页数:23
相关论文
共 205 条
[1]   Distribution of cyclosporin in organ transplant recipients [J].
Akhlaghi, F ;
Trull, AK .
CLINICAL PHARMACOKINETICS, 2002, 41 (09) :615-637
[2]   The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus [J].
Akhlaghi, Fatemeh ;
Dostalek, Miroslav ;
Falck, Pal ;
Mendonza, Anisha E. ;
Amundsen, Rune ;
Gohh, Reginald Y. ;
Asberg, Anders .
THERAPEUTIC DRUG MONITORING, 2012, 34 (01) :38-45
[3]   Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients [J].
Alak, AM ;
Moy, S .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (05) :2487-2490
[4]   Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].
Amirimani, B ;
Ning, B ;
Deitz, AC ;
Weber, BL ;
Kadlubar, FF ;
Rebbeck, TR .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305
[5]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[6]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[7]   Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients [J].
Antignac, Marie ;
Barrou, Benoit ;
Farinotti, Robert ;
Lechat, Philippe ;
Urien, Saik .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (06) :750-757
[8]  
Aplin AE, 2002, J CELL SCI, V115, P2781
[9]   Renal failure after clinical heart transplantation is associated with the TGF-β1 codon 10 gene polymorphism [J].
Baan, CC ;
Balk, AHMM ;
Holweg, CTJ ;
van Riemsdijk, IC ;
Maat, LPWM ;
Vantrimpont, PJMJ ;
Niesters, HGM ;
Weimar, W .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (09) :866-872
[10]   IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation [J].
Bamoulid, Jamal ;
Courivaud, Cecile ;
Deschamps, Marina ;
Mercier, Patricia ;
Ferrand, Christophe ;
Penfornis, Alfred ;
Tiberghien, Pierre ;
Chalopin, Jean-Marc ;
Saas, Philippe ;
Ducloux, Didier .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08) :2333-2340